Drugs / EpCAM CAR-T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02915445 | Jul 2016 → Jul 2025 | breast cancer, gastric cancer, malignant tumor of nasopharynx | Sichuan University | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EpCAM CAR-T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02915445 ↗ |
| Action | Deplete | “The engineered T cells were then endowed cytotoxicity to the tumor cells” NCT02915445 ↗ |
| Modality | Cell therapy | “engineered T cells armed with chimeric antigen receptor (CAR-T)” NCT02915445 ↗ |
| Target | EPCAM | “CAR recognizing EpCAM” NCT02915445 ↗ |